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Abstract
Background: The coexistence of type 2 diabetes mellitus and hypertension increases the risk of cardiovascular diseases.
The U.K. Prospective Diabetes Study has shown that blood pressure control as well as blood glucose control is efficient
for prevention of complications in hypertensive patients with diabetes mellitus. However, some reports have shown that
it is difficult to control the blood pressure and the concomitant use of a plurality of drugs is needed in hypertensive
patients with diabetes mellitus. In recent years renin-angiotensin system depressants are increasingly used for the blood
pressure control in diabetic patients. Particularly in Japan, angiotensin II (A II) antagonists are increasingly used. However,
there is no definite evidence of the point of which is efficient for the control, the increase in dose of A II antagonist or
the concomitant use of another drug, in hypertensive patients whose blood pressure levels are inadequately controlled
with A II antagonist.
Methods/Design: Hypertensive patients of age 20 years or over with type 2 diabetes mellitus who have been treated
by the single use of AII antagonist at usual doses for at least 8 weeks or patients who have been treated by the
concomitant use of AII antagonist and an antihypertensive drug other than calcium channel blockers and ACE inhibitors
at usual doses for at least 8 weeks are included.
Discussion: We designed a multi-center, prospective, randomized, open label, blinded-endpoint trial, ADVANCED-J, to
compare the increases in dose of A II antagonist and the concomitant use of a Ca-channel blocker (amlodipine) and A II
antagonist in hypertensive patients with diabetes mellitus, whose blood pressure levels were inadequately controlled with
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A II antagonist. This study is different from the usual previous studies in that home blood pressures are assessed as
indicators of evaluation of blood pressure. The ADVANCED-J  study may have much influence on selection of
antihypertensive drugs for treatment in hypertensive patients with diabetes mellitus. It is expected to give an important
hint for considering the validity of selection of antihypertensive drugs from the aspects not only of the antihypertensive
effect but medical cost-effectiveness.
Background
It has been revealed by many epidemiological studies
including the Framingham study that diabetes mellitus
(DM) and hypertension (HT) are respectively risk factors
of cardiovascular diseases and that the coexistence of DM
with HT considerably increases the risk of cardiovascular
diseases [1-4]. The results of the U.K. Prospective Diabetes
Study (UKPDS) suggest that blood pressure control, rather
than blood glucose control, is efficient for prevention of
macrovascular complications of those of DM, which
include stroke and myocardial infarction[5]. The results of
the Hypertension Optimal Treatment (HOT)-study on the
correlation between optimum target blood pressure levels
and the occurrence of cardiovascular events also suggest
that it is useful for HT patients with DM to set the target
levels lower than those for general HT patients[6]. Aggres-
sive antihypertensive therapy needs to be carried out.
On the basis of these knowledge, observations, and find-
ings, optimum target blood pressure levels for HT patients
with DM (DM+HT patients) are set at 130/80 mm Hg
lower than those for general HT patients in various guide-
lines [7-10]. While optimum target blood pressure levels
for DM+HT patients are set at lower levels, it is known that
it is difficult to control blood pressure in these patients.
The results of many large-scale clinical studies have shown
that the combined use of a plurality of antihypertensive
drugs is actually needed to blood pressure control.
The types of antihypertensive drugs that are recom-
mended to the treatment of DM+HT patients vary with
guidelines, but in many cases renin-angiotensin (RA) sys-
tem depressants and calcium channel blockers (Ca block-
ers) are recommended, taking into consideration the
influence on glucose metabolism.
Angiotensin II (A II) is a peptide hormone closely
involved with the Na excretion control via the RA system.
A II is widely recognized from the action mechanism to
influence the onset and exacerbation of HT. ACE inhibi-
tors suppressing A II production and A II receptor antago-
nists (A II antagonists) have been developed as
antihypertensive drugs suppressing the RA system, and
used all over the world [5,11,12]. It has also been shown
that A II has an adverse influence on carbohydrate metab-
olism. These RA system depressants may also be expected
to improve glucose tolerance in DM patients, and the fre-
quency of the drugs used is being increased [13-18].
On the other hand, Ca antagonists exert the antihyperten-
sive action to wide-ranging patients, and are commonly
used as antihypertensive drugs through the mechanism of
inhibiting calcium entry, which triggers constriction in
vascular smooth muscle cells. Ca antagonists are recom-
mended as a therapeutic medicine for DM+HT patients,
because they have no adverse influence on lipid metabo-
lism or glucose metabolism [19-28].
In recent years, the use of A II antagonists as antihyperten-
sive drugs for DM+HT patients is being increased in Japan.
The increase in dose of antihypertensive drug, the com-
bined use of antihypertensive drugs with different mecha-
nisms, and so on, are considered as methods to respond
to the inadequate control of blood pressure in HT
patients. However, there is no distinct evidence of the
measure that will make better control of blood pressure to
become a reality in DM+HT patients, whose blood pres-
sure is inadequately controlled with A II antagonist.
In hypertensive patients whose blood pressure levels were
inadequately controlled by single therapy with an A II
antagonist, we designed the ADVANCED-J study to com-
pare different methods for antihypertensive therapy, i.e.,
the increase in dose of A II antagonist and the combined
use of a Ca blocker amlodipine, which is most frequently
used in Japan, in terms of the usefulness.
Methods/Design
Study population
Subjects are recruited in outpatient offices of university
hospitals or general hospitals from the entire apectrum of
patients with coexistent hypertension and type 2 diabetes
mellitus.
Inclusion criteria
The patients, who are judged as meeting all of the follow-
ing conditions by investigators, are included in the study.
1) Patients with type 2 diabetes mellitus
2) Patients who have been treated by the single use of AII
antagonist (Nu-lotan Tablet, i.e., a losartan potassium
preparation, is used in the patients who start receivingBMC Cardiovascular Disorders 2006, 6:39 http://www.biomedcentral.com/1471-2261/6/39
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treatment from the observation period) at usual doses for
at least 8 weeks (including the observation period of 2
weeks or more for the study) or patients who have been
treated by the concomitant use of AII antagonist and an
antihypertensive drug other than calcium channel block-
ers and ACE inhibitors at usual doses for at least 8 weeks
(including the observation period of 2 weeks or more for
the study).
3) Patients who show > 135 mm Hg systolic or > 85 mm
Hg diastolic of the ambulatory blood pressure levels
measured (in the sitting position) at the time of start of
the observation period, and show > 130 mm Hg systolic
or > 80 mm Hg diastolic of the mean (home blood pres-
sure level measured after getting up before the start of
study) of the home blood pressure levels after getting up
for the last 5 days during the last 2-week observation
period.
4) Patients whose consent is obtained at age 20 years or
over.
5) Patients whose consent is obtained from themselves in
written form.
With regard to 2) and 3), however, the case, which shows
> 180 mm Hg systolic or > 110 mm Hg diastolic of the
mean of the home blood pressure levels measured after
getting up for the last 5 days during the first 1-week obser-
vation period, is included in the study.
Exclusion criteria
This study excludes the patients who are judged as being
conformed to one of the following conditions by investi-
gators.
1) Patients with secondary hypertension.
2) Patients who show > 180 mm Hg systolic or > 110 mm
Hg diastolic of the ambulatory blood pressure levels
measured (in the sitting position) at the time of start of
the observation period.
3) Patients with severe hepatic dysfunction.
4) Patients with severe renal dysfunction.
5) Patients with a past history of hypersensitiveness to
study drugs.
6) Pregnant, lactating, and probably pregnant patients,
and patients who want to become pregnant during the
study period.
7) Patients who have attended other trials within 3
months before the start of the observation period or who
attend other trials simultaneously with the present study.
8) Other patients judged as being inappropriate for the
subjects of the study by investigators.
Allocation procedure
Investigators confirm that the subjects are consistent with
the inclusion criteria and are not contrary to the exclusion
criteria and input necessary matters on the Web before the
start of the study (before the start of the period when the
dose is increased or other concomitant drug is used). The
results of the dynamic allocation to two groups according
to the eligibility of the relevant patient to the study and
background factors (Increased AII antagonist dose group
and combined amlodipine group) are indicated on the
Web by E-mail.
The urinary albumin levels during the observation period
(< 300 mg/g Cre, > 300 mg/g Cre) and systolic blood pres-
sure levels (< 135 mm Hg, 135 mm Hg ) of the home
blood pressure levels after getting up before the start of the
study are taken into consideration on allocation of the
patients (into the increased AII antagonist dose group and
the combined amlodipine group).
Study drugs
The following commercially-available drugs are used as
study drugs in the study (See Table 1,2):
Dosage regimen of study drugs and administration period
(1) Dosage regimen
With regard to the time of oral administration (direction
for use), the study drug is taken after breakfast or after get-
ting up once a day.
The dose of AII antagonist in the increased AII antagonist
dose group is the maximum dose approved. However, in
the cases in which the antihypertensive effect is excessive
(< 110 mm Hg systolic or < 65 mm Hg diastolic of the
home blood pressure after getting up), and in which the
dose is required to be reduced, the dose of AII antagonist
may be reduced.
The dose of AII antagonist in the combined amlodipine
group is the same as that (usual dose) during the observa-
tion period, and the dose of amlodipine is 5 mg/day.
However, in the cases in which the antihypertensive effect
is excessive (< 110 mm Hg systolic or < 65 mm Hg diasto-
lic of the home blood pressure* after getting up) and in
which the dose is required to be reduced, the dose of
amlodipine may be reduced (See Table 3).BMC Cardiovascular Disorders 2006, 6:39 http://www.biomedcentral.com/1471-2261/6/39
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* Note: The mean of the blood pressure levels measured
for the last 5 days during the 2-week period throughout
the study period.
(2) Administration period
Three years after the start of study.
Target blood pressure levels
The home blood pressure levels after getting up are < 125
mm Hg systolic and < 80 mm Hg diastolic.
* Note: The mean of the levels measured for the last 5
days during the 2-week period (during the 14-day period
between 14 days before the day of ambulatory examina-
tion and the previous day of the ambulatory examination
day) before the ambulatory examination day (the refer-
ence day of the months without ambulatory examina-
tion).
Other concomitant drug and combined therapy
(1) The following drugs may be concomitantly used with
AII antagonist under individual conditions
1) Antihypertensive drugs used concomitantly with AII
antagonist before the start of the observation period (The
drugs other than calcium channel blockers and ACE
inhibitors)
2) Antihypertensive drugs other than the study drug from
8 weeks onward after the start of the study.
3) Drugs used for the treatment of complications
(2) The drugs prohibited to be concomitantly used
Antihypertensive drugs other than the study drug for 8
weeks after the start of the study.
(3) Combined therapy
Combined therapy including standard diet therapy, ther-
apeutic exercise, prohibition of smoking, etc. is not
restricted.
Steps to increase doses of the study drug and 
antihypertensive drugs other than the study drug and to 
Table 2: List of calcium channel blocker
Generic name Study drug name (Brand name) Active ingredient content Manufacturers/distributors
amlodipine besilate Amlodin® tablets 2.5 containing 2.5 mg of amlodipine Sumitomo Pharmaceuticals Co., Ltd.
Amlodin® tablets 5 containing 5 mg of amlodipine
Norvasc® tablets 2.5 mg containing 2.5 mg of amlodipine Pfizer Japan Inc.
Norvasc® tablets 5 mg containing 5 mg of amlodipine
Table 1: List of AII receptor antagonists
Generic name Study drug name (Brand name) Active ingredient content Manufacturers/distributors
candesartan cilexetil Blopress® tablets 2 containing 2 mg of candesartan cilexetil Takeda Pharmaceutical Co., Lid.
Blopress® tablets 4 containing 4 mg of candesartan cilexetil
Blopress® tablets 8 containing 8 mg of candesartan cilexetil
Blopress® tablets 12 containing 12 mg of candesartan cilexetil
losartan potassium Nu-lotan® tablets 25 containing 25 mg of losartan potassium Banyu Pharmaceutical Co., Ltd.
Nu-lotan® tablets 50 containing 50 mg of losartan potassium
telmisartan Micardis® capsules 20 mg containing 20 mg of telmisartan Nippon Boehringer Ingelheim Co., Ltd./
Yamanouchi Pharmaceutical Co., Ltd. 1)
Micardis® capsules 40 mg containing 40 mg of telmisartan
valsartan Diovan® tablets 20 mg containing 20 mg of valsartan Nihon Chiba-Geigy K.K./Novartis Pharma 
K.K.
Diovan® tablets 40 mg containing 40 mg of valsartan
Diovan® tablets 80 mg containing 80 mg of valsartan
olmesartan medoxomil Olmetec® tablets 10 mg containing 10 mg of olmesartan medoxomil Sankyo Co., Ltd.
Olmetec® tablets 20 mg containing 20 mg of olmesartan medoxomil
1) After April 1, 2005, Astellas Pharma Inc.BMC Cardiovascular Disorders 2006, 6:39 http://www.biomedcentral.com/1471-2261/6/39
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use concomitantly an antihypertensive drug other than the 
study drug
A chart of steps to increase doses of the study drug and
antihypertensive drugs other than the study drug and to
use concomitantly an antihypertensive drug other than
the study drug is shown below (See Figure 1).
Study period
Between the time of obtainment of the patients' consent
and the end of the (3-year) period of the increase in dose
or the concomitant use (However, the 2-year period from
one year onward after the start of the study is the follow-
up study period).
Outcome measures
(1) Outcome measures for efficacy
Main outcome measures
• Changes in the home blood pressures after getting up
(home blood pressure levels)
￿ The rate of home blood pressure levels accomplishing
the target levels (< 125 mm Hg systolic and < 80 mm Hg
diastolic)
Secondary outcome measures
￿ Changes in the blood pressure levels measured on an
outpatient basis (ambulatory blood pressure level)
￿ The rate of the ambulatory blood pressure levels accom-
plishing the reference levels (< 130 mm Hg systolic and <
80 mm Hg diastolic)
￿ Changes in the home blood pressures before going to
bed
￿ Changes in IMT of the cervical artery
￿ Changes in PWV
￿ Changes in echocardiographic findings
￿ Changes in urinary albumin level
￿ Changes in BNP
￿ Changes in hs-CRP
￿ Medical cost-effectiveness
(2) Outcome measures for safety
￿ Adverse events, adverse drug reactions
￿ Clinical laboratory data
Statistical analysis
(1) Transaction of cases
The Clinical Protocols Committee and members of the
Clinical Protocols Preparation Subcommittee decide the
transaction of the cases and to fix the data collected for 12
months and 36 months after the start of the study.
(2) Population to be analyzed
1) Population to be analyzed for efficacy
￿ The major population to be analyzed for efficacy
includes those defined according to the principle of inten-
tion-to-treat principle.
2) Population to be analyzed for safety
￿ The population to be analyzed for safety include the
population in which the dose of the AII antagonist is
increased or the additional concomitant use of
amlodipine is conducted after the start of the study.
(3) Statistical analysis design
Main outcome measures and analytical methods:
Table 3: Dosage regimens of study drugs for two groups
Study drug Dosage and administration (oral) Usual daily dose
Increased AII antagonist dose group Combined amlodipine group
Blopress® tablets o.d. 12 mg 8 mg
Nu-lotan® tablets o.d. 100 mg 50 mg
Micardis® capsules o.d. 80 mg 40 mg
Diovan® tablets o.d. 160 mg 80 mg
Olmetec® tablets o.d. 40 mg 20 mg
Amlodin® tablets, or Norvasc® tablets o.d. n/a 5 mg
1) The approved maximum daily dose
2) The upper limit of the usual daily doses approved for AII antagonistsBMC Cardiovascular Disorders 2006, 6:39 http://www.biomedcentral.com/1471-2261/6/39
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1) Main outcome measures
(a) Changes in the home blood pressures after getting up
(home blood pressure level)
(b) The rate of home blood pressure levels accomplishing
the target levels
2) Analytical methods
Steps to increase doses of study drug and antihypertensivedrugs other than the study drug and to use other concomitant drug Figure 1
Steps to increase doses of study drug and antihypertensivedrugs other than the study drug and to use other concomitant drug. 
1) In the case in which the systolic blood pressure (mean level of the levels measured for last 5 days) measured at home after 
getting up for a week after the start of observation period is > 180 mm Hg or the diastolic blood pressure level is > 110 mm 
Hg, the case may be assigned to the treated group. 2, 3) Only when the blood pressure level does not reach the target systolic 
and diastolic blood pressure measured at home after getting up are < 125 mm Hg and < 80 mm Hg, respectively). 2) The com-
bined use of renin-angiotensin inhibitors (ACE inhibitors, AII antagonist) is prohibited. 3) The combined use of calcium channel 
blocker is prohibited.
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With regard to (a), the subjects include "the population to
be analyzed for efficacy", and summarized statistics about
difference in blood pressure (the extent of antihyperten-
sive effect) at each instant of survey are calculated from
blood pressure at each instant of survey and from blood
pressure levels during the observation period. Analysis of
variance is applied for the inter-group comparison. In
each group the blood pressure levels during the observa-
tion period are compared with the blood pressure levels at
the instant of survey for reference. The extent of antihyper-
tensive effect is also compared between the groups at each
instant of survey. With regard to (b), the subjects include
"the population to be analyzed for efficacy", and the rates
of the blood pressure levels measured 8 and 12 months
after the start of the study, which accomplish the target
blood pressure levels, are calculated and the frequencies
with which the rates are obtained are compared by χ2 test.
Secondary outcome measures and analytical methods:
1) Secondary outcome measures
(a) Changes in ambulatory blood pressure levels
(b) The rate of ambulatory blood pressure levels accom-
plishing the reference levels
(c) Changes in home blood pressure levels measured
before going to bed
(d) Changes in carotid IMT
(e) Changes in PWV
(f) Changes in echocardiographic findings
(g) Changes in urinary albumin level
(h) Changes in BNP
(i) Changes in hs-CRP
(j) Medical cost-effectiveness
2) Analytical methods
With regard to items (a) and (c), the analysis includes "the
population to be analyzed
for efficacy", and conforms to " (3) 1) (a) Changes in
blood pressure levels measured
at home after getting up". With regard to item (b), the
analysis includes "the
population to be analyzed for efficacy", and conforms to
"(3) 1) (b) The rate of home
blood pressure levels accomplishing the target levels".
With regard to items (d)
through (i), the analysis includes "the population to be
analyzed for efficacy", and the
blood pressure levels during the observation period are
compared with those at each
time point of survey in each group. The difference
between the blood pressure level
during the observation period and that at each instant of
survey is compared
between the groups. With regard to item (j), the analysis
includes "the population to
be analyzed for efficacy", and the drugs used, the contents
of events, and medical
fees required are compiled according to groups for com-
parison.
Analysis period
The statistical analysis follows the fixation of the data col-
lected for 12 months after the start of the study and of the
data collected (for 36 months after the start of the study)
during the follow-up period.
Target number of the patients
The target number of the patients is 300 patients consist-
ing of 150 in the increased AII antagonist dose group and
150 in the combined amlodipine group.
Discussion and conclusion
Significance of the ADVANCED-J study
Selection of methods for antihypertensive therapy has
been a matter of controversy, but the results of meta-anal-
ysis of the Blood Pressure Lowering Treatment Trialists'
Collaboration (BPLTTC), in which the results of large-
scale clinical studies in recent years were comprehensively
interpreted, have suggested that the way to decrease the
blood pressure, rather than the types of antihypertensive
drugs, is important for prevention not only of stroke but
of coronary arterial diseases such as myocardial infarc-
tion. When the efficacy of the initiated antihypertensive
drug is inadequate, physicians adopt either the increase in
dose of the antihypertensive drug or the combined use of
another antihypertensive drug with the initiated drug as
alternative choices. However, there are hardly any studies
on comparison of these alternatives in terms of the anti-BMC Cardiovascular Disorders 2006, 6:39 http://www.biomedcentral.com/1471-2261/6/39
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hypertensive effect or the influence on cardiovascular
events.
Some reports have shown that the combined use of anti-
hypertensive drugs is needed to particularly HT patients
with DM or nephropathy. Of these drugs, A II antagonists
have been reported to have favorable influence on the
renal function. In recent years the use of A II antagonists
is increasingly used as the first-line medicine for HT
patients with DM or nephropathy. On the other hand, it
is also true that there are many patients who receive treat-
ment by the combined use of a Ca blocker with the antag-
onist in many studies of evaluation of the efficacy of these
drugs. The results of the meta-analysis in recent years have
suggested that adequate control of blood pressure levels is
also necessary for adequate exertion of the usefulness of
RA system depressants in hypertensive patients.
While it has been reported that there is correlation
between the antihypertensive action and the dose of A II
antagonists, some reports have shown that the increase in
the antihypertensive effect is limited even by the increase
in dose to more than the usual dose. Since an adverse
effect of ACE inhibitors, a dry cough, is frequently
observed in Japanese people, the shift to A.R.B. rapidly
proceeded. However, NHI drug price of A.R.B. is high.
With regard to the use at dose more than the usual dose,
its efficacy needs to be reviewed from a viewpoint of med-
ical cost-effectiveness. Based on the background, the
ADVANCED-J study was designed to compare the increase
in dose of A II antagonists and the combined use of
amlodipine with an antagonist in terms of the antihyper-
tensive effect in hypertensive patients whose blood pres-
sure levels were inadequately controlled by single therapy
with an A II antagonist.
Assessment of the home blood pressure
The primary outcome measure of the ADVANCED-J study
included the home blood pressure measured in the early
morning. The prevalence of home blood pressure monitor
in recent years has allowed comprehension of details of
the blood pressure condition. As a result, the presence of
so-called masked hypertension, which shows the inade-
quately controlled home blood pressure in spite of the
controlled ambulatory blood pressure, has increasingly
been revealed.
It has been reported that the risk of cardiovascular events
in masked hypertension patients is as high as that in per-
sistent hypertension patients. The importance of 24-hour
blood pressure control involving home blood pressure is
increasingly recognized. In fact, it is not realistic on a
point of principle or from the aspect of medical cost-effec-
tiveness to conduct the ambulatory blood pressure moni-
toring (ABPM) in all hypertensive patients. On the other
hand, at least 30,000,000 home blood pressure monitors
have been put on the market up to date in Japan, and it
can be said from the global aspect that they have become
more widespread in Japan. The blood pressure levels
measured with home blood pressure monitors, particu-
larly those measured at the time of rising in the morning,
have been reported to reflect changes in blood pressure
during the course from the night to the early morning. The
correlation between blood pressure levels at home in the
morning and the onset of cardiovascular events has also
been reported. It is considered important for suppression
of cardiovascular events in HT patients with DM to con-
trol the home blood pressures measured in the morning.
There are many DM patients who show the non-dipper
type of changes in blood pressure, i.e., the type which
shows an only slight spontaneous decrease in blood pres-
sure during the night (because of poor control of the auto-
nomic nervous system and of renal hypofunction), and
the home blood pressures measured in the morning are
predicted to be high in them. It is therefore considered
important for prevention of the onset of cardiovascular
events to control the home blood pressure measured in
the morning even in HT patients with DM.
However, there have been only few or no comparative
studies on drugs, which have focused on home blood
pressures measured in the morning in HT patients with
DM. There have been no studies on the point of which is
more efficient for controlling of home blood pressures
measured in the early morning, the increase in dose of A
II antagonists or the additional combined use of a Ca
blocker. Based on these circumstances, the home blood
pressures in the morning were adopted to evaluation of
blood pressure control in this study.
The compliance of recording by patients and bias due to
selection of levels at the time of data recording have influ-
ence on reliability of the measurement of blood pressure
levels at home. For this reason, the i-monitoring system
was adopted to the ADVANCED-J study, and all the blood
pressure levels measured were semiautomatically accumu-
lated in the Data Center. All the data from the measure-
ments and the summary data were supplied to physicians
via web when necessary.
Assessment of arteriosclerosis
It has been believed that arteriosclerosis is more likely to
progress in DM patients. According to Kawamori et al., it
is clear that intimal-medial thickening (IMT), i.e., an indi-
cator of systemic arteriosclerosis, has been increased even
in the pre-stage of DM (IFG, IGT). As methods of assessing
arteriosclerosis in the coronary artery, various techniques,
such as quantitative coronary arteriography, intravascular
ultrasonography, multi-slice CT, MRI, etc., have beenBMC Cardiovascular Disorders 2006, 6:39 http://www.biomedcentral.com/1471-2261/6/39
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developed. It is impossible to widely use these techniques
because of some problems with invasion to patients,
exposure to radiation and magnetism, etc. and of proce-
dural complexity of measurement. The assessment of IMT
by cervical arterial echography or the evaluation of
baPWV by measurements of pulse waves at the wrist and
ankle yields no invasion to patients. These techniques are
methods of assessing arteriosclerosis, which rarely allow
physical load to patients. Even for general clinics, these
techniques are the less invasive methods for assessment,
which are simple to maneuver. IMT and baPWV were
applied as indicators in this study, and the influence of
antihypertensive therapy on progression of arteriosclero-
sis was also evaluated.
Conclusion
The ADVANCED-J study is a prospective clinical study
that is designed to compare the increase in dose of A II
antagonist and the combined use of a Ca blocker,
amlodipine, in terms of the efficacy for blood pressure
control in DM+HT patients whose blood pressure levels
are inadequately controlled by the single treatment with
an A II antagonist. This study is different from the usual
previous studies in that home blood pressures are assessed
as indicators of evaluation of blood pressure.
The ADVANCED-J study may have much influence on
selection of antihypertensive drugs for treatment in HT
patients with DM. It is expected to give an important hint
for considering the validity of selection of antihyperten-
sive drugs from the aspects not only of the antihyperten-
sive effect but medical cost-effectiveness.
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